This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrial fibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. Piccini, M.D.,
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
PFA is designed to address AFib, the most common arrhythmia in the US, with a growing patient population. Antiarrhythmic drugs are typically a poor solution for AFib, as their side effects can be debilitating. The operational and safety benefits are “nice,” but AFib ablation has never really been a dangerous procedure.
The patient characteristics, AF effect on quality-of-life questionnaire (AFEQT), and ablation strategies performed remains uncertain in those with and without HFrEF. Catheter ablation (CA) for atrial fibrillation (AF) and heart failure with reduced ejection fraction <40% (HFrEF) is associated with improved outcomes.
OSA is commonly seen in patients with arrhythmias like atrial fibrillation (AFib) and due to the variable unpredictable nature of sleep apnea symptoms, it is often untreated, leading to adverse outcomes. Western Regional Director of Cardiac Electrophysiology, Northwell Health , NY.
Image courtesy: Getty Images christine.book Sat, 05/18/2024 - 14:26 May 18, 2024 — The Heart Rhythm Society ( HRS ) has announced the findings of three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation ( AFib ).
(Harvard University Heart Letter) A clinical polygenic risk score test for diseases ranging from atrial fibrillation (AFib) to breast cancer was piloted by scientists. Patients with obstructive hypertrophic cardiomyopathy who underwent surgical myectomy reported improved quality of life.
AFib Facts and Impacts Atrial fibrillation is the most common cardiac arrhythmia, affecting 2% of individuals worldwide. It is also published in Heart Rhythm , the official journal of the HRS, Journal of Arrhythmia , the official journal of the APHRS, and Journal of Interventional Cardiac Electrophysiology , the official journal of the LAHRS.
A stroke is often a devastating occurrence for several reasons: A stroke can be life threatening and stroke is widely recognised as a leading cause of death worldwide A stroke can be disabling and can destroy a person’s quality of life A stroke can recur and cause more damage/death the next time. This is called cardioembolism.
The final STEP-HFpEF substudy found semaglutide to be especially effective at improving quality of life in patients with both AFib and obesity-related HFpEF. Semaglutide improved KCCQ-CSS scores, especially in patients with AFib.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content